Sanofi shakes up clinical plans for trio of programs from Denali, Principia and Kymab deals
AcquisitionIPO
In its third-quarter report, Sanofi disclosed it ended enrollment in a study investigating alomfilimab, an anti-ICOS mAb that it got from its $1.5 billion Kymab buyout, for the treatment of solid tumors. The decision was not based on any observed safety signal, the company added, though it didn’t provide any more details.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.